Skip to content

Anti-mullerian Hormone (AMH) After Treatment of Endometriomas With Alcohol Sclerotherapy Versus Surgery: Clinical Trial

Anti-mullerian Hormone in Ovarian Reserve Evaluation After Treatment of Endometriomas With Alcohol Sclerotherapy Versus Surgery: Clinical Trial

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03571776
Enrollment
158
Registered
2018-06-28
Start date
2018-06-05
Completion date
2023-01-15
Last updated
2023-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrioma, Fertility Disorders

Brief summary

The purpose of this multicenter study is to compare the ovarian reserve after alcohol sclerosis of the endometriomas against conventional surgery (AMH, follicle stimulating hormone (FSH) and antral follicles count) as well as the complications and costs between the 2 procedures.

Detailed description

Clinical Trial Phase III, Multicenter, National, open, parallel-group assignment 1: 1, stratified by age, previous oophorectomy and uni- or bilateral ovarian involvement. Patients with suspected ovarian endometrioma by ultrasound will be randomized into 2 groups: (a) Study Group: echoguided aspiration plus sclerosis with alcohol; (B) Control group: Laparoscopic Cystectomy. Pre-treatment, and 6 months after treatment, AMH values will be determined. Complications, recurrences and costs from each treatment will be collected.

Interventions

PROCEDURESurgery

Laparoscopic ovarian cystectomy

PROCEDURESclerotherapy

US-aspiration and alcohol sclerosis

Sponsors

Hospital Universitari de Bellvitge
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Multicenter, National, assignment 1: 1, stratified by age, previous oophorectomy and uni- or bilateral ovarian involvement.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Uni- or bilocular endometrioma according ultrasounds * Endometrioma size: 30-100 mm when symptoms were present and 50-100 mm if asymptomatics * \> 3 months from diagnosis * Ca125 \<200 IU/mL and human epididymis protein 4 (HE4) \< 70,

Exclusion criteria

* Previous gynecological cancer * Symptomatic severe extraovarian endometriosis * Dermoid or high risk of malignancy cysts * Pregnancy * Mental disability

Design outcomes

Primary

MeasureTime frameDescription
Change from Baseline AMH Testprior and 6 months after both proceduresthe value of AMH in ng/mL

Secondary

MeasureTime frameDescription
Change from Baseline antral follicles countprior and 6 months after both proceduresUS antral follicles count
Complications1 month after the procedurenumber of participants with complications
Costs1 month after the procedurecosts (euros) of the procedure plus cost of their complications
Change from Baseline Painprior and 6 months after both proceduresVisual Analog Score for pain (ranged 1-10). Patients pain evaluation fron 1 no pain to 10 maximum pain considered

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026